Type 2 diabetes drug a ‘game changer’

A relatively new drug has been found to greatly reduce risk of cardiovascular and kidney disease – though it comes with risks of its own Canagliflozin (Invokana) is a SGLT2 inhibitor that works by blocking the body’s reabsorption of sugar or glucose, resulting in a drop in glucose levels. Results from two trials run across